TNS quantifies Avandia cardiac toll

Reports linking GlaxoSmithKline's Avandia to increased cardiovascular risk, and the drug's subsequent swoon, may prove just the tip of the iceberg for the diabetes field. Marketing research firm TNS says recent events will lead to more instability.

“The market upheaval is likely to continue and grow, as negative news hits about other diabetes drugs—such as the recent withdrawal of Exubera and concerns over Byetta's potential link to acute pancreatitis,” said Philip O'Hagan, TNS Healthcare international client services director.

In the third quarter, after the media reports linking Avandia circulated, TNS saw a dramatic turnaround, with the majority of Avandia changes coming from doctors withdrawing patients from the drug. Potential cardiac issues drove 21% of those changes. That data point came from TNS' DiabetesDynamics USA, a quarterly resource which tracks therapy changes and their causes in the type 2 diabetes market.

You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.